Related Articles for PubMed (Select 18755024)

Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA.

Lancet. 2005 Feb 19-25;365(9460):671-9.

PMID: 15721472 [PubMed - indexed for MEDLINE]

Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer.

Karlsson E, Delle U, Danielsson A, Olsson B, Abel F, Karlsson P, Helou K.

BMC Cancer. 2008 Sep 8;8:254.

PMID: 18778486 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.

Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, van de Vijver MJ.

Eur J Surg Oncol. 1999 Aug;25(4):356-63.

PMID: 10419704 [PubMed - indexed for MEDLINE]

Predictive value of bone marrow accumulation of Tc-99m tetrofosmin for subsequent development of distant metastases in breast cancer.

Wakasugi S, Tsukuma H, Inaji H, Hashizume T, Noguchi A, Ohnishi T.

Ann Nucl Med. 2007 Oct;21(8):429-37. Epub 2007 Oct 25.

PMID: 17952551 [PubMed - indexed for MEDLINE]

10:

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID: 17993229 [PubMed - indexed for MEDLINE]

11:

Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.

Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM.

J Clin Oncol. 2003 May 15;21(10):1973-9.

PMID: 12743151 [PubMed - indexed for MEDLINE]

12:

C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis.

Pinto AE, André S, Pereira T, Nóbrega S, Soares J.

Ann Oncol. 2001 Apr;12(4):525-33.

PMID: 11398888 [PubMed - indexed for MEDLINE]

13:

Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup.

Nicholson S, Richard J, Sainsbury C, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon JR, Harris AL.

Br J Cancer. 1991 Jan;63(1):146-50.

PMID: 1846551 [PubMed - indexed for MEDLINE]

14:

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2008 Jul 31. [Epub ahead of print]

PMID: 18668363 [PubMed - as supplied by publisher]

15:

A consensus prognostic gene expression classifier for ER positive breast cancer.

Teschendorff AE, Naderi A, Barbosa-Morais NL, Pinder SE, Ellis IO, Aparicio S, Brenton JD, Caldas C.

Genome Biol. 2006;7(10):R101. Epub 2006 Oct 31.

PMID: 17076897 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

16:

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.

Järvinen TA, Holli K, Kuukasjärvi T, Isola JJ.

Br J Cancer. 1998 Jun;77(12):2267-73.

PMID: 9649144 [PubMed - indexed for MEDLINE]

17:

Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.

Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown AM.

J Clin Oncol. 2006 Dec 20;24(36):5637-44. Epub 2006 Nov 20.

PMID: 17116944 [PubMed - indexed for MEDLINE]

18:

Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.

Esteban JM, Felder B, Ahn C, Simpson JF, Battifora H, Shively JE.

Cancer. 1994 Sep 1;74(5):1575-83.

PMID: 7914825 [PubMed - indexed for MEDLINE]

19:

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.

Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van't Veer LJ; On behalf of the TRANSBIG consortium.

Breast Cancer Res Treat. 2008 Jul 27. [Epub ahead of print]

PMID: 18661261 [PubMed - as supplied by publisher]

20:

HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.

Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.

Breast Cancer Res Treat. 2008 May;109(2):351-7. Epub 2007 Jul 18.

PMID: 17636399 [PubMed - indexed for MEDLINE]

Recent Activity